News | March 13, 2024
Nirma acquires majority stake in Glenmark Life Sciences
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
Completes acquisition of 75% of share capital from Glenmark Pharmaceuticals
These approvals mark significant progress for Venus Remedies in expanding its market presence
This agreement paves the way for the introduction of YESAFILI into the Canadian market
The agreement licenses the company to launch in the United States, in February 2025, once approved by the U.S. FDA
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
These re-agent and diagnostic test kits come with 99.7% accuracy
Developed by Pfizer, Abrocitinib has received marketing authorization from the Central Drugs Standard Control Organization (CDSCO) in India
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Subscribe To Our Newsletter & Stay Updated
